Form 13-F position report

ELICIO THERAPEUTICS INC

Reported by Steward Partners Investment Advisory LLC

ELTX CUSIP 28657F103 Manager CIK 0001723397

Reported 2,023 shares, unchanged from the prior quarter.

Reported value -63.4%; share count 0.0% vs. the prior quarter.

Unchanged
% of reported 13F value < 0.01% This manager · Q2 2026
Shares 2,023 Quarter-end amount reported
Reported value $7,910 Fair value at quarter end
Consecutive quarters held 13 Through Q2 2026

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2023-06-30 14763
2023-09-30 13131
2023-12-31 12960
2024-03-31 11810
2024-06-30 6387
2024-09-30 7817
2024-12-31 7925
2025-03-31 9573
2025-06-30 11997
2025-09-30 17001
2025-12-31 12370
2026-03-31 21626
2026-06-30 7910
2026-09-30 3682

Quarterly position history

How this manager's reported quarter-end position changed over time.

14 quarters
Quarterly reported position history for ELICIO THERAPEUTICS INC held by Steward Partners Investment Advisory LLC.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q3 2026 Unchanged 2,023 0 (0.0%) < 0.01% $3,682 2026-11-13
Q2 2026 Unchanged 2,023 0 (0.0%) < 0.01% $7,910 2026-08-13
Q1 2026 Added 2,023 +469 (30.2%) < 0.01% $21,626 2026-05-08
Q4 2025 Unchanged 1,554 0 (0.0%) < 0.01% $12,370 2026-02-12
Q3 2025 Unchanged 1,554 0 (0.0%) < 0.01% $17,001 2025-11-12
Q2 2025 Unchanged 1,554 0 (0.0%) < 0.01% $11,997 2025-08-12
Q1 2025 Unchanged 1,554 0 (0.0%) < 0.01% $9,573 2025-05-13
Q4 2024 Unchanged 1,554 0 (0.0%) < 0.01% $7,925 2025-02-06
Q3 2024 Unchanged 1,554 0 (0.0%) < 0.01% $7,817 2024-11-14
Q2 2024 Unchanged 1,554 0 (0.0%) < 0.01% $6,387 2024-08-08
Q1 2024 Unchanged 1,554 0 (0.0%) < 0.01% $11,810 2024-05-15
Q4 2023 Unchanged 1,554 0 (0.0%) < 0.01% $12,960 2024-02-12
Q3 2023 Unchanged 1,554 0 (0.0%) < 0.01% $13,131 2023-11-13
Q2 2023 New 1,554 +1,554 (0.0%) < 0.01% $14,763 2023-08-14

Who else reported the position

72 managers reported ELICIO THERAPEUTICS INC for Q2 2026.

Managers reporting ELICIO THERAPEUTICS INC in Q2 2026.
Manager Activity Shares Change % of reported 13F Reported value Tenure
Knoll Capital Management LLC Added 1,211,957 +581,042 2.21% $4,738,751 6 qtrs
BlackRock Inc Added 766,005 +715,408 < 0.01% $2,995,079 8 qtrs
VANGUARD CAPITAL MANAGEMENT LLC Added 572,151 +53,513 < 0.01% $2,237,110 2 qtrs
GEODE CAPITAL MANAGEMENT LLC Added 311,354 +176,190 < 0.01% $1,217,614 13 qtrs
STATE STREET CORPORATION Added 179,420 +128,800 < 0.01% $701,532 10 qtrs
NORTHERN TRUST CORPORATION Added 130,162 +70,428 < 0.01% $508,933 9 qtrs
Ikarian Capital LLC New 100,000 +100,000 0.04% $391,000 1 qtr
VANGUARD PORTFOLIO MANAGEMENT LLC New 88,905 +88,905 < 0.01% $347,619 1 qtr
VANGUARD FIDUCIARY TRUST CO Added 88,062 +18,873 < 0.01% $344,322 2 qtrs
ALLIANCEBERNSTEIN L P New 81,280 +81,280 < 0.01% $317,805 1 qtr
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
June 30, 2026
Filed
August 13, 2026
Filing type
13F-HR
Position type
COM

Voting authority reported

Sole
0
Shared
0
None
2,023

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.